<p>Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the respiratory tract and is associated with an increased risk of lung cancer. Non-small cell lung cancer (NSCLC) patients with COPD have been shown to exhibit favorable responses to anti-PD-1/PD-L1 therapy. In the present study, we investigated T cell profiles and functions in the lung tissues of NSCLC patients with or without COPD to provide the rationale for immunotherapy of NSCLC patients with COPD. Abundant PD-1<sup>+</sup> and Tim-3<sup>+</sup> T cells were detected in the lung tumor tissues of NSCLC patients with COPD. On the other hand, CD103<sup>+</sup> tissue-resident memory T (T<sub>RM</sub>) cells in non-tumor lung tissues were more abundant in NSCLC patients with than in those without COPD. Furthermore, the abundance of CD103<sup>+</sup> T<sub>RM</sub> cells in non-tumor lung tissues correlated with IFN-γ production and COPD-related clinical parameters (pack-years smoking history and the FEV1/FVC ratio). In NSCLC patients with COPD, T cells were active participants in both the non-tumor and the lung tumor tissues, suggesting the potential response to immunotherapy.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Lung tissue T cells are activated in chronic obstructive pulmonary disease with non-small cell lung cancer patients

  • Mari Tone,
  • Tomomi Isono,
  • Yoko Yamamoto,
  • Yoshito Takeda,
  • Yasushi Shintani,
  • Atsushi Kumanogoh,
  • Hisashi Wada,
  • Kota Iwahori

摘要

Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the respiratory tract and is associated with an increased risk of lung cancer. Non-small cell lung cancer (NSCLC) patients with COPD have been shown to exhibit favorable responses to anti-PD-1/PD-L1 therapy. In the present study, we investigated T cell profiles and functions in the lung tissues of NSCLC patients with or without COPD to provide the rationale for immunotherapy of NSCLC patients with COPD. Abundant PD-1+ and Tim-3+ T cells were detected in the lung tumor tissues of NSCLC patients with COPD. On the other hand, CD103+ tissue-resident memory T (TRM) cells in non-tumor lung tissues were more abundant in NSCLC patients with than in those without COPD. Furthermore, the abundance of CD103+ TRM cells in non-tumor lung tissues correlated with IFN-γ production and COPD-related clinical parameters (pack-years smoking history and the FEV1/FVC ratio). In NSCLC patients with COPD, T cells were active participants in both the non-tumor and the lung tumor tissues, suggesting the potential response to immunotherapy.